Paclitaxel Injection (INTAXEL) is indicated as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary. As first-line therapy, Paclitaxel Injection is indicated in combination with cisplatin.
Paclitaxel Injection (INTAXEL) is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy.
Paclitaxel Injection (INTAXEL) is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
Paclitaxel Injection (INTAXEL) in combination with cisplatin, is indicated for the first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy.
Paclitaxel Injection (INTAXEL) is indicated for the second-line treatment of AIDS- related Kaposi's sarcoma.
30 mg/5ml, 100 mg/17ml and 260 mg/43.4 ml vials individually packaged in a carton.